超级皇冠网分布图-皇冠网hg9388.com_百家乐统计工具_全讯网帝国cms网站源 (中国)·官方网站

師資

EN       返回上一級       師資搜索
洪鑫
助理教授
hongx@sustech.edu.cn

個人簡介:

洪鑫博士是南方科技大學(xué)醫(yī)學(xué)院生物化學(xué)系助理教授(Tenure-track A/P),副研究員,博士生導(dǎo)師,于2013年博士畢業(yè)于新加坡國立大學(xué),2014-2020年博士后期間在哈佛醫(yī)學(xué)院/霍華德醫(yī)學(xué)研究中心 (HHMI) 致力于癌癥轉(zhuǎn)移生物學(xué)機制和循環(huán)腫瘤細(xì)胞(CTC)液體活檢技術(shù)的研發(fā),相關(guān)成果發(fā)表在 Cell、 Cancer Discovery、 PNAS、 EMBO Journal、 Genes & Development 等國際著名期刊,引用超過1700次 (H-index = 21),并獲得了多個國際和國內(nèi)獎項和榮譽,包括新加坡國立大學(xué)最佳畢業(yè)生獎(Lijen Industrial Development Award, NUS), 新加坡科研局青年基金(A*STAR JCO early career development award)以及美國癌癥協(xié)會 (AACR) 的青年學(xué)者獎項 (AACR Scholar-In-Training Award)。本課題組近3年獲批主持/承擔(dān)國家級項目5項,包括國家基金委外國優(yōu)秀青年學(xué)者項目、面上/青年項目、以及科技部重點研發(fā)等共10余項科研基金,擁有3項國際專利。

 

教育背景:

2008 – 2013              博士,生物醫(yī)學(xué),新加坡國立大學(xué), 新加坡

2002 – 2006              榮譽學(xué)士,生物學(xué),新加坡國立大學(xué),新加坡

 

工作經(jīng)歷:

08/2020 – 至今           助理教授,博士生導(dǎo)師,南方科技大學(xué)醫(yī)學(xué)院,中國

07/2014 – 05/2020     HHMI 博士后,麻省總醫(yī)院癌癥中心/哈佛醫(yī)學(xué)院,美國

04/2013 – 06/2014     過渡博士后, 新加坡科研局(A*STAR)/新加坡國立大學(xué),新加坡

 

獲獎情況及榮譽:

2020            美國癌癥協(xié)會(AACR) Scholar-In-Training Award,美國

2013            新加坡科研局(A*STAR)青年基金(JCO Career Development Award), 新加坡

2007-2010   研究生獎學(xué)金(Junior Research Fellowship),淡馬錫生命科學(xué)實驗室(TLL),新加坡

2006             新加坡國立大學(xué)本科最佳畢業(yè)設(shè)計獎(LiJen Industrial Development Medal), 新加坡

2002-2006   教育部留學(xué)生獎學(xué)金(本科),新加坡教育部

 

研究領(lǐng)域:

癌癥轉(zhuǎn)移機制,液體活檢術(shù),循環(huán)腫瘤細(xì)胞 (CTC)

  1. 建立基于CTC的癌轉(zhuǎn)移動物模型(CDX),研究CTC介導(dǎo)的癌遠(yuǎn)程轉(zhuǎn)移分子生物學(xué)機制

  2. 結(jié)合新一代微流控CTC芯片技術(shù)和單細(xì)胞組學(xué)繪制CTC轉(zhuǎn)移和增殖的癌細(xì)胞進(jìn)化圖譜

  3. 液體活檢技術(shù)開發(fā)

  4. 開發(fā)和篩選抑制CTC遠(yuǎn)程轉(zhuǎn)移的小分子藥物


學(xué)術(shù)任職:

Theranostics  (客座編輯,2021-2022)

BMC Cancer (副主編/編委,2022-至今)

Cancer Drug Resistance(青年編委,2022-至今)

Aging & Disease (青年編委,2023-至今)

iMeta, 青年編委 (2024-至今)

發(fā)表論文:

* first/co-first authors; # corresponding/co-corresponding authors

1. Xu K*, Liu X*, Zeng Q*, Liu Y, Shan L, Ji L, Wu Y, Wu J, Chen Y, Li Y, Huang S, Jiang C, Hong X#, Wu C#, Wang Z#. Cannabinoid CB2 receptor controls chronic itch by regulating spinal microglial activation and synaptic transmission. Cell Rep. 2025 Apr 11;44(4):115559. (*Equal contributions; #co-corresponding authors)

2. Zhen Zhan, Yuting Wang, Hanhan Xie, Ming Yang, Muyang Ruan, Xuefei Liu, Jialing Liu, Zeyang Liu, Feiqiu Wen, Xin Hong#, Chengzhi Hu#. Hierarchically Porous Microgels with Interior Spiral Canals for High-Efficiency Delivery of Stem Cells in Wound Healing. Small. 2024 Dec 19:e2405648. (*Equal contributions; #co-corresponding authors)

3. Yufan Yang*, Guanyin Huang*, Jingru Lian*, Chunhao Long, Boxi Zhao, Xuefei Liu, Binyu Zhang, Weijian Ye, Junhao Chen, Longxiang Du, Zhuofeng Jiang, Jialing Liu, Jianglin Zhang, Chengzhi Hu#, Qingfeng Chen#, Xin Hong#. Circulating tumour cell clusters: isolation, biological significance and therapeutic implications. BMJ Oncology. 2024;3:e000437. (*Equal contributions; #co-corresponding authors)

4. Hemi Luan*, Shuailong Chen*, Jingru Lian*, Boxi Zhao, Xiaolong Xu, Yafei Chen, Yufang Yang, Zhuofeng Jiang, Min Qi, Jialing Liu, Wenyong Zhang, Tiangang Luan, Xin Hong#. Biofluorescence imaging-guided spatial metabolic tracing: In vivo tracking of metabolic activity in circulating tumor cell-mediated multi-organ metastases. Talanta. 2024 Aug 10;280:126696. (*Equal contributions; #co-corresponding authors)

5. Ye L*, Jiang Z*, Zheng M, Pan K, Lian J, Ju B, Liu X, Tang S, Guo G, Zhang S, Hong X#, Lu W#. Fatty acid metabolism-related lncRNA prognostic signature for serous ovarian carcinoma. Epigenomics. 2024 Feb 15. (#co-corresponding authors)

6. Jiang Z*, He J*, Zhang B*, Wang L, Long C, Zhao B, Yang Y, Du L, Luo W#, Hu J#, Hong X#. A Potential "Anti-Warburg Effect" in Circulating Tumor Cell-mediated Metastatic Progression? Aging Dis. 2024 Jan 11. (*Equal contributions;#co-corresponding authors)

7. Fox DB*, Ebright RY*, Hong X*, Russell HC, Guo H, LaSalle TJ, Wittner BS, Poux N, Vuille JA, Toner M, Hacohen N, Boland GM, Sen DR, Sullivan RJ, Maheswaran S#, Haber DA#. Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. NPJ Precis Oncol. 2023 Mar 2;7(1):25.(*Equal contributions;#co-corresponding authors)

8. Hong X*, Roh W*, Sullivan R J, Wong K H K, Wittner B S, Guo H, Dubash T D, Sade-Feldman M, Wesley B, Horwitz E, Boland G M, Marvin D L, Bonesteel T, Lu C, Aguet F, Burr R, Freeman S S, Parida L, Calhoun K, Jewett M K, Nieman L T, Hacohen N, Naar A M, Ting D T, Toner M, Stott S L, Getz G, Maheswaran S, Haber D A. The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. Cancer Discovery, 2021 Mar;11(3):678-695.(*Equal contributions)

9. Hong X*, Sullivan RJ*, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S**, Haber DA**. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2467-2472. (*Equal contributions; **co-corresponding authors)

10. Hong X*, Nguyen HT*, Chen Q, Zhang R, Hagman Z, Voorhoeve PM, Cohen SM. Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover. EMBO J. 2014 Nov 3;33(21):2447-57. (*Equal contributions)

11. Nguyen HT*, Hong X*, Tan S, Chen Q, Chan L, Fivaz M, Cohen SM, Voorhoeve PM. Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition of the YAP proto-oncogene. Cell Rep. 2014 Aug 7;8(3):707-13. (*Equal contributions)

12. Herranz H*, Hong X*, Hung NT, Voorhoeve PM, Cohen SM. Oncogenic cooperation between SOCS family proteins and EGFR identified using a Drosophila epithelial transformation model. Genes Dev. 2012 Jul 15;26(14):1602-11. (* Equal contributions)

13. Hong X*, Hammell M*, Ambros V, Cohen SM. Immunopurification of Ago1 miRNPs selects for a distinct class of microRNA targets. Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):15085-90. (*Equal contributions)

14. Liu J, Lian J, Chen Y, Zhao X, Du C, Xu Y, Hu H, Rao H, Hong X#. Circulating Tumor Cells (CTCs): A Unique Model of Cancer Metastases and Non-invasive Biomarkers of Therapeutic Response. Frontiers in Genetics, 2021 Aug 25;12:734595.(#corresponding authors)

15. Hu J, He P, Zhao F, Lin W, Xue C, Chen J, Yu Z, Ran Y, Meng Y, Hong X, Shum PP, Shao L. Magnetic microspheres enhanced peanut structure cascaded lasso shaped fiber laser biosensor for cancer marker-CEACAM5 detection in serum. Talanta. 2024 Jan 5;271:125625.

16. Yuan S*, Xi S*, Weng H*, Guo MM, Zhang JH, Yu ZP, Zhang H, Yu Z, Xing Z, Liu MY, Ming DJ, Sah RK, Zhou Y, Li G, Zeng T, Hong X, Li Y, Zeng XT, Hu H. YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancer. Cell Death Differ. 2023 Dec;30(12):2477-2490.(*Equal contributions)

17. Guo H S*, Golczer G*, Wittner B, Langenbucher A, Zachariah M, Dubash T D, Hong X, Comaills V, Burr R, Ebright R Y, Horwitz E, Vuille J A, Hajizadeh S, Wiley D F, Reeves B A, Zhang J M, Niederhoffer K L, Lu C Y, Wesley B, Ho U, Nieman L T, Toner M, Vasudevan S, Zou L, Mostoslavsky R, Maheswaran S**, Lawrence M S**, Harber D A**. NR4A1 regulates expression of immediate early genes, suppressing replication stress in cancer. Molecular Cell, 2021 Oct 7;81(19):4041-4058.e15.(*Equal contributions;**co-corresponding authors)

18. Xu H*, Li S*, Sun Y*, Xu L, Hong X, Wang Z, Hu H. ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer. Cancers, 2021 Aug 5;13(16):3957. (*Equal contributions)

19. Che J, Hong X, Rao H. PCNA Ubiquitylation: Instructive or Permissive to DNA Damage Tolerance Pathways?. Biomolecules, 2021 Oct 19;11(10):1543.

20. Edd JF, Mishra A, Dubash TD, Herrera S, Mohammad R, Williams EK, Hong X, Mutlu BR, Walsh JR, Machado de Carvalho F, Aldikacti B, Nieman LT, Stott SL, Kapur R, Maheswaran S, Haber DA, Toner M. Microfluidic concentration and separation of circulating tumor cell clusters from large blood volumes. Lab Chip. 2020 Feb 7;20(3):558-567.

21. Aya-Bonilla CA, Morici M, Hong X, McEvoy AC, Sullivan RJ, Freeman J, Calapre L, Khattak MA, Meniawy T, Millward M, Ziman M, Gray ES. Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. Br J Cancer. 2020 Mar;122(7):1059-1067.

22. Yan C*, Brunson DC*, Tang Q*, Do D*, Iftimia NA, Moore JC, Hayes MN, Welker AM, Garcia EG, Dubash TD, Hong X, Drapkin BJ, Myers DT, Phat S, Volorio A, Marvin DL, Ligorio M, Dershowitz L, McCarthy KM, Karabacak MN, Fletcher JA, Sgroi DC, Iafrate JA, Maheswaran S, Dyson NJ, Haber DA, Rawls JF, Langenau DM. Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell. 2019 Jun 13;177(7):1903-1914.e14. (*Equal contributions).

23. Miyamoto DT*, Lee RJ*, Kalinich M, LiCausi JA, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, McGovern FJ, Efstathiou JA, Smith MR, Sequist LV, Kapur R, Wu CL, Stott SL, Ting DT, Giobbie-Hurder A, Toner M, Maheswaran S**, Haber DA**. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discov. 2018 Mar;8(3):288-303. (*Equal contributions; ** co-corresponding authors).

24. Kalinich M*, Bhan I*, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, Milner JD, Hong X, Goyal L, Sil S, Choz M, Ho U, Kapur R, Muzikansky A, Zhang H, Weitz DA, Sequist LV, Ryan DP, Chung RT, Zhu AX, Isselbacher KJ, Ting DT, Toner M, Maheswaran S**, Haber DA**. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1123-1128. (*Equal contributions; ** co-corresponding authors).

25. Thanh Nguyen H, Andrejeva D, Gupta R, Choudhary C, Hong X, Eichhorn PJ, Loya AC, Cohen SM. Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnover. Cell Discov. 2016 Mar 29;2:16001. doi: 10.1038/celldisc.2016.1.

26. Ge W, Deng Q, Guo T, Hong X, Kugler JM, Yang X, Cohen SM. Regulation of pattern formation and gene amplification during Drosophila oogenesis by the miR-318 microRNA. Genetics. 2015 May;200(1):255-65.

27. Herranz H, Hong X, Cohen SM. Mutual repression by bantam miRNA and Capicua links the EGFR/MAPK and Hippo pathways in growth control. Curr Biol. 2012 Apr 24;22(8):651-7.

28. Becam I*, Rafel N*, Hong X, Cohen SM, Milán M. Notch-mediated repression of bantam miRNA contributes to boundary formation in the Drosophila wing. Development. 2011 Sep;138(17):3781-9. (*Equal contributions).

29. Herranz H, Hong X, Pérez L, Ferreira A, Olivieri D, Cohen SM, Milán M. The miRNA machinery targets Mei-P26 and regulates Myc protein levels in the Drosophila wing. EMBO J. 2010 May 19;29(10):1688-98.

30. Tang ZZ, Liao P, Li G, Jiang FL, Yu D, Hong X, Yong TF, Tan G, Lu S, Wang J, Soong TW. Differential splicing patterns of L-type calcium channel Cav1.2 subunit in hearts of Spontaneously Hypertensive Rats and Wistar Kyoto Rats. Biochim Biophys Acta. 2008 Jan;1783(1):118-30.

31. Tang ZZ, Hong X, Wang J, Soong TW. Signature combinatorial splicing profiles of rat cardiac- and smooth-muscle Cav1.2 channels with distinct biophysical properties. Cell Calcium. 2007 May;41(5):417-28.


彩票预测| 网上百家乐内| 网上百家乐优博| 德州扑克游戏网站| 百家乐官网变牌器| 黄金城百家乐下载| 仙居县| 百家乐平台有什么优势| 百家乐赌场合作| bet365注册哪家好| 澳门百家乐官网出千吗| 大发888玩哪个| 百家乐官网棋牌正式版| 威尼斯人娱乐城真钱百家乐| 百家乐官网自动下注| 大发888官网多少| 澳门百家乐官网规| 易发百家乐| 中国百家乐的玩法技巧和规则| 如何赢百家乐官网的玩法技巧和规则 | 大发888备用网| 七胜百家乐娱乐城总统网上娱乐城大都会娱乐城赌场 | 蒲江县| 手机百家乐官网的玩法技巧和规则 | 百家乐官网赌博赌博平台| 百家乐赢家球讯网| 虚拟百家乐官网游戏下载| 大发888送58彩金| 玩百家乐保时捷娱乐城| 澳门百家乐官网然后赢| 云鼎百家乐的玩法技巧和规则| 百家乐官网QQ群娱乐| 澳门百家乐官网鸿福厅| 澳门永利| 威尼斯人娱乐场棋牌| 百家乐官网赌博技巧网| 勃利县| 大发888客服电话 在线| 赌百家乐容易的原| 网上百家乐玩法| 最佳场百家乐官网的玩法技巧和规则 |